60 Degrees Pharmaceuticals, Inc. (SXTPW)
| Market Cap | 3.16M -13.5% |
| Revenue (ttm) | 1.21M +63.9% |
| Net Income | -8.62M |
| EPS | -5.41 |
| Shares Out | 3.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.0246 |
| Day's Range | n/a |
| 52-Week Range | 0.0220 - 0.1499 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About SXTPW
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zi... [Read more]
News
60 Degrees Pharmaceuticals Transcript: Study update
The DSMB recommended completing the blinded hospital study, with no safety signal; follow-up of 30 patients is planned before unblinding in early 2027. The first three expanded access patients were reported cured, with two more outcomes expected in November.
60 Degrees Pharmaceuticals Press release: Study update
60 Degrees Pharmaceuticals issued a press release on October 6, 2026, disclosing material business information to investors.
60 Degrees Pharmaceuticals to conclude enrollment in tafenoquine study
60 Degrees Pharmaceuticals (SXTP) announced that it intends to conclude enrollment in its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis at 30 subjects. The c...
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains...
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis ( NCT06207370) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6...
60 Degrees Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A clinical development campaign aims to expand ARAKODA's label from malaria to babesiosis, supported by promising early trial results and a strong safety profile. Key regulatory milestones are expected over the next 18 months, with a potential product launch in early 2028.
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
60 Degrees Pharma (Nasdaq: SXTP) will present on demand at H.C. Wainwright beginning Sept. 11 and hold 1 x 1 investor meetings Sept. 14–16 in New York.
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne dise...
60 Degrees Pharmaceuticals Registration statement: Registration filing
60 Degrees Pharmaceuticals filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
60 Degrees Pharmaceuticals Quarterly report: Q2 2026
60 Degrees Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
60 Degrees Pharmaceuticals Earnings release: Q2 2026
60 Degrees Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
60 Degrees Pharmaceuticals to sell shares and warrants in private placement
60 Degrees Pharmaceuticals (SXTP) announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock or pre-funded warrants…
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medi...
60 Degrees Pharma babesiosis interim readout planned by October 6
60 Degrees Pharmaceuticals (SXTP) announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis. The out...
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE ...
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline.
60 Degrees Pharmaceuticals Proxy statement: Proxy filing
60 Degrees Pharmaceuticals filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
60 Degrees Pharmaceuticals announces DSMB recommendation for B-Free study
60 Degrees Pharmaceuticals (SXTP) announced that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study, following a review of safety data fro...
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicin...
60 Degrees Pharmaceuticals Slides: Investor presentation
60 Degrees Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
60 Degrees executes patent licensing agreement with Florida State
60 Degrees Pharmaceuticals (SXTP) announced that the company has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify...
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter i...
60 Degrees Pharmaceuticals Proxy statement: Proxy filing
60 Degrees Pharmaceuticals filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
60 Degrees announces early enrollment of first patient in trial of tafenoquine
60 Degrees Pharmaceuticals (SXTP) announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy...
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-...